Invitrogen Corp.
Invitrogen Corp. of Carlsbad, Calif.,
has entered into an agreement with the National Institutes of Health Chemical Genomics
Center in Bethesda, Md., to identify small molecules that modulate key signaling
pathways associated with disease pathophysiology. The center will use the company’s
CellSensor cell lines and GeneBLAzer β-lactamase reporter gene technology
to identify compounds that modulate disease signaling pathways. All of the data
will be deposited in PubChem, an NIH database that links chemical structures to
biological activities uncovered through screening campaigns. The research community
will have access to the database.
LATEST NEWS